Showing 301 - 320 results of 16,593 for search '(( 50 ((026 decrease) OR (a decrease)) ) OR ( 50 ((nn decrease) OR (we decrease)) ))', query time: 0.53s Refine Results
  1. 301

    DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  2. 302

    DataSheet2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  3. 303

    DataSheet3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  4. 304

    DataSheet1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  5. 305

    DataSheet6_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  6. 306

    DataSheet4_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  7. 307

    Data_Sheet_1_Propofol EC50 for inducing loss of consciousness in patients under combined epidural-general anesthesia or general anesthesia alone: a randomized double-blind study.do... by Jiangling Wang (11929476)

    Published 2023
    “…The epidural anesthesia on the general anesthetic (GA) requirements has not been well investigated. Therefore, we conducted the present study to explore the predicted effect-site concentration of propofol (Ce<sub>prop</sub>) required for achieving the loss of consciousness (LOC) in 50% of patients (EC<sub>50</sub>) with or without epidural anesthesia.…”
  8. 308

    The decreasing rates of V<sub>p</sub> with temperature. by Nazlı Tunar Özcan (14833635)

    Published 2023
    “…The V<sub>p</sub> and the σ<sub>t</sub> of Çankırı rock salt decrease with increasing temperatures of samples whereas the σ<sub>c</sub> increases. …”
  9. 309
  10. 310
  11. 311
  12. 312
  13. 313
  14. 314

    Data_Sheet_1_Sleeping <6.55 h per day was associated with a higher risk of low back pain in adults aged over 50 years: a Korean nationwide cross-sectional study.PDF by Dexin Hu (19710271)

    Published 2024
    “…</p>Conclusion<p>Our findings indicate that shorter sleep duration is a risk factor for LBP in adults aged over 50 years. …”
  15. 315
  16. 316
  17. 317
  18. 318

    3D-Printed Diamond–Titanium Composite: A Hybrid Material for Implant Engineering by Kate Fox (1793524)

    Published 2019
    “…Using this method, we could prepare composite scaffolds of up to 50% diamond, which has never been achieved before. …”
  19. 319
  20. 320